JP2009528030A - １型糖尿病の診断、予防及び治療において用いられる転写因子Ａｒｎｔｌ２遺伝子及びその発現産物 - Google Patents

１型糖尿病の診断、予防及び治療において用いられる転写因子Ａｒｎｔｌ２遺伝子及びその発現産物 Download PDF

Info

Publication number
JP2009528030A
JP2009528030A JP2008555900A JP2008555900A JP2009528030A JP 2009528030 A JP2009528030 A JP 2009528030A JP 2008555900 A JP2008555900 A JP 2008555900A JP 2008555900 A JP2008555900 A JP 2008555900A JP 2009528030 A JP2009528030 A JP 2009528030A
Authority
JP
Japan
Prior art keywords
diabetes
arntl2
gene
seq
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008555900A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009528030A5 (enExample
Inventor
アヴナー，フィリップ
ログナー，ユテ，クリスティーヌ
フン，ミン−シウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur
Original Assignee
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur filed Critical Institut Pasteur
Publication of JP2009528030A publication Critical patent/JP2009528030A/ja
Publication of JP2009528030A5 publication Critical patent/JP2009528030A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Environmental Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Husbandry (AREA)
  • Biophysics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
JP2008555900A 2006-02-27 2007-02-27 １型糖尿病の診断、予防及び治療において用いられる転写因子Ａｒｎｔｌ２遺伝子及びその発現産物 Withdrawn JP2009528030A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77666206P 2006-02-27 2006-02-27
PCT/IB2007/001649 WO2007099461A2 (en) 2006-02-27 2007-02-27 Transcription factor arntl2 gene and expression products thereof used in the diagnosis, prevention, and treatment of type 1 diabetes

Publications (2)

Publication Number Publication Date
JP2009528030A true JP2009528030A (ja) 2009-08-06
JP2009528030A5 JP2009528030A5 (enExample) 2010-04-02

Family

ID=38442622

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008555900A Withdrawn JP2009528030A (ja) 2006-02-27 2007-02-27 １型糖尿病の診断、予防及び治療において用いられる転写因子Ａｒｎｔｌ２遺伝子及びその発現産物

Country Status (7)

Country Link
US (2) US20090181915A1 (enExample)
EP (1) EP1994174B1 (enExample)
JP (1) JP2009528030A (enExample)
AT (1) ATE485399T1 (enExample)
CA (1) CA2638825A1 (enExample)
DE (1) DE602007009944D1 (enExample)
WO (1) WO2007099461A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602007009944D1 (de) 2006-02-27 2010-12-02 Pasteur Institut Gen des transkriptionsfaktors arntl2 sowie bei der diagnose, vorbeugung und behandlung von typ-1-diabetes verwendete expressionsprodukte davon
CN109295210A (zh) * 2018-10-30 2019-02-01 深圳市万众基因转化医学研究院 一种人类2型糖尿病相关基因突变筛查的组合引物及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3769465B2 (ja) * 2001-02-13 2006-04-26 独立行政法人科学技術振興機構 新規時計遺伝子Ｂｍａｌ２
WO2006019824A2 (en) * 2004-07-15 2006-02-23 Joslin Diabetes Center, Inc. Methods of treating diabetes
DE602007009944D1 (de) 2006-02-27 2010-12-02 Pasteur Institut Gen des transkriptionsfaktors arntl2 sowie bei der diagnose, vorbeugung und behandlung von typ-1-diabetes verwendete expressionsprodukte davon

Also Published As

Publication number Publication date
DE602007009944D1 (de) 2010-12-02
US20090181915A1 (en) 2009-07-16
CA2638825A1 (en) 2007-09-07
US20070214510A1 (en) 2007-09-13
EP1994174A2 (en) 2008-11-26
EP1994174B1 (en) 2010-10-20
ATE485399T1 (de) 2010-11-15
WO2007099461A2 (en) 2007-09-07
US7960107B2 (en) 2011-06-14
WO2007099461A3 (en) 2007-12-27
HK1126251A1 (en) 2009-08-28

Similar Documents

Publication Publication Date Title
Azzedine et al. Mutations in MTMR13, a new pseudophosphatase homologue of MTMR2 and Sbf1, in two families with an autosomal recessive demyelinating form of Charcot-Marie-Tooth disease associated with early-onset glaucoma
Jobard et al. Identification of mutations in a new gene encoding a FERM family protein with a pleckstrin homology domain in Kindler syndrome
Thiselton et al. An integrated, functionally annotated gene map of the DXS8026–ELK1 interval on human Xp11. 3–Xp11. 23: Potential hotspot for neurogenetic disorders
Oberkofler et al. Complex haplotypes of the PGC-1α gene are associated with carbohydrate metabolism and type 2 diabetes
Taylor et al. Evolutionary constraints on the Disrupted in Schizophrenia locus
Haase et al. The murine NF2 homologue encodes a highly conserved merlin protein with alternative forms
EP1891237B9 (en) Enpp1 (pc-1) gene haplotype associated with the risk of obesity and type 2 diabetes and their applications
Urano et al. SLC25A24 as a novel susceptibility gene for low fat mass in humans and mice
US20040018493A1 (en) Haplotypes of the CD3E gene
Conteduca et al. The role of AIRE polymorphisms in melanoma
EP1994174B1 (en) Transcription factor arntl2 gene and expression products thereof used in the diagnosis, prevention, and treatment of type 1 diabetes
JP2003509052A (ja) ＡＭＰＫのγ鎖の変異体、それをエンコードするＤＮＡ配列及びその使用
Kovacs et al. Polymorphisms in the oxygen-regulated protein 150 gene (ORP150) are associated with insulin resistance in Pima Indians
Desjardins et al. Genetic variants and haplotype analyses of the ZBRK1/ZNF350 gene in high‐risk non BRCA1/2 French Canadian breast and ovarian cancer families
WO2008039445A9 (en) Polymorphisms in the human xbp-1 gene are associated with inflammatory bowel disease
EP2129801B1 (en) Tbc1d1 as a diagnostic marker for obesity or diabetes
Rüstemoglu et al. Analysis of common MDR1 (ABCB1) gene C1236T and C3435T polymorphisms in Turkish patients with familial Mediterranean fever
Hong et al. RAPGEF1 gene variants associated with type 2 diabetes in the Korean population
Saleh et al. Prevalence of PPAR-γ2 (rs1801282), RETN (rs3745367) and ADIPOQ (rs2241766) SNP markers in the Bangladeshi type 2 diabetic population
PT2220256E (pt) Método in vitro para o diagnóstico de cancro da pele
Al Hussieny et al. The Association Between genetic variations of KCNj11 gene and type 2 diabetes mellitus in a sample of Iraqi population.
HK1126251B (en) Transcription factor arntl2 gene and expression products thereof used in the diagnosis, prevention, and treatment of type 1 diabetes
US20030207284A1 (en) Haplotypes of the UCP2 gene
JP4444576B2 (ja) ２型糖尿病関連遺伝子
EP2212439B1 (en) Zfp69,znf642 and znf643 as markers for obesity-associated diabetes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100205

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20120111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120111